Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9fb7bbc09927d64558e1e99a3b7c719b |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1246 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6843 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6811 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-645 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 |
filingDate |
2022-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2022-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_baefdef4d5128c29f892f0fb22b89efe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e55cddca26b4777155b2badd56c08ac |
publicationDate |
2022-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-11492391-B1 |
titleOfInvention |
Intracellular nanobody targeting T4SS effector inhibits ehrlichia infection |
abstract |
Infection with obligatory intracellular bacteria is difficult to treat as intracellular targets and delivery methods of therapeutics are not well-known. Ehrlichia translocated factor-1 (Etf-1), a type IV secretion system (T4SS) effector, is a primary virulence factor for an obligatory intracellular bacterium, Ehrlichia chaffeensis. Disclosed herein are Etf-1-specific nanobodies (Nbs) that block Etf-1 functions and Ehrlichia infection. Also disclosed is a method for treating human monocytic ehrlichiosis (HME) in a subject with the disclosed nanobodies. |
priorityDate |
2021-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |